Asthma and COPD Drugs Market to Be Worth 4.1% by 2024
The U.S. and China market for asthma and COPS drugs is anticipated to showcase a steep trajectory for growth in the coming years. According to a report by Transparency Market Research (TMR), the leading companies in the U.S. and China asthma and COPD drugs market accounted for just under 64.0% in 2015, demonstrating the consolidated nature of this industry, along with high levels of competition among the established players. Merck & Co. Inc., Novartis AG, Astrazeneca plc, GlaxoSmithKline plc and...
View full press release